Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Hybrid |
|
as soon as is submitted to ZB.
Peripheral metabolism informs on future cognitive decline and development of Alzheimer’s disease in population at risk.
Alzheimers Dement. 20, 1:e089802 (2025)
BACKGROUND: Peripheral metabolic health status can reflect and/or contribute to the risk of Alzheimer's disease (AD). Peripheral metabolic health status can be indicated by metabolic health markers, such as inflammatory biomarker glycoprotein acetyls (GlycA) and specific components of lipoproteins (e.g., triacylglycerol of high-density lipoprotein). However, it is unclear if the relationship between peripheral metabolism and AD-related markers is heterogenous among diverse populations and throughout the disease progression. METHODS: Utilizing Alzheimer's Disease Neuroimaging Initiative data, we determined whether baseline plasma GlycA can inform on cognitive and brain structural changes among sub-populations with different diagnosis status. Furthermore, correlation analyses were performed between blood metabolomics and cerebrospinal fluid (CSF) proteomics data in sub-populations with different diagnosis status or different mild cognitive impairment (MCI)/AD outcomes in 3 years. RESULTS: GlycA was elevated in AD patients compared to cognitively normal participants. Baseline GlycA level was associated with executive function decline at 3-9 year follow-up in participants diagnosed with late mild cognitive impairment (LMCI) at baseline, with similar but not identical trends observed in the future decline of memory and entorhinal cortex volume. In addition, peripheral metabolomics signatures of CSF proteomics were well-distinguished between cognitive normal participants and AD patients. Moreover, different peripheral-central metabolic connection was also observed in MCI-AD converters vs. MCI-MCI non-converters across 3 years follow up. CONCLUSION: Peripheral inflammation was linked to future cognitive decline and brain structural atrophy for population at risk. In addition, peripheral metabolomics-CSF proteomics correlation reveals distinguishing peripheral-central connection patterns in AD patients as well as MCI participant soon to develop AD in 3 years. Findings here point to peripheral systemic inflammation and metabolic health in general as risk factors in AD development, pointing to therapeutic intervention related to periphery metabolic health for patients at risk.
Impact Factor
Scopus SNIP
Altmetric
11.100
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Language
english
Publication Year
2025
HGF-reported in Year
2025
ISSN (print) / ISBN
1552-5260
e-ISSN
1552-5279
Journal
Alzheimer's & Dementia
Quellenangaben
Volume: 20,
Article Number: e089802,
Supplement: 1
Publisher
Elsevier
Publishing Place
New York, NY [u.a.]
Reviewing status
Peer reviewed
Institute(s)
Institute of Computational Biology (ICB)
POF-Topic(s)
30205 - Bioengineering and Digital Health
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-503891-001
PubMed ID
39751544
Erfassungsdatum
2025-03-18